Exosome Drug Developer Capricor Therapeutics Inc (CAPR) is Initiated by ROTH Capital to Buy

June 16, 2016 Leave a comment 2,094 Views

from The Market Digest by Robert Westfall Capricor Therapeutics Inc (CAPR) was Initiated by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Jun 15, 2016. Capricor Therapeutics Inc opened for trading at $3.31 ...

Exosome RNA Exosome RNA Research & Industry News

Tag Archives: CSps

Exosome Drug Developer Capricor Therapeutics Inc (CAPR) is Initiated by ROTH Capital to Buy

MSC extracellular vesicle therapy developed at Boston Children’s stops preeclampsia before it starts

The microfluidic toolbox for analyzing exosome biomarkers

Identification of a novel RNA aptamer that selectively targets breast cancer exosomes

Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes

Functional single-cell profiling identifies that exosomes are associated with increased immune cell infiltration in non-metastatic breast cancer

Liquid biopsy-based exo-oncomiRNAs can predict prostate cancer aggressiveness